Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer

NCT02174549 is registered in ClinicalTrials.gov with Teclison Ltd. as lead sponsor.

NCT NCT02174549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02174549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer
Lead sponsor
Teclison Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 30, 2014
Completion date
September 30, 2028
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal cancer metastatic, hepatocellular carcinoma, neuroendocrine tumors